166 related articles for article (PubMed ID: 32209103)
1. A micro-elimination approach to addressing hepatitis C in Turkey.
Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
[TBL] [Abstract][Full Text] [Related]
2. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
Schaefer B; Viveiros A; Al-Zoairy R; Blach S; Brandon S; Razavi H; Dorn L; Finkenstedt A; Effenberger M; Graziadei I; Sarcletti M; Tilg H; Zoller H
PLoS One; 2018; 13(7):e0200750. PubMed ID: 30001427
[TBL] [Abstract][Full Text] [Related]
3. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
[TBL] [Abstract][Full Text] [Related]
4. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Kondili LA; Blach S; Razavi H; Craxì A
Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
[TBL] [Abstract][Full Text] [Related]
5. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
[TBL] [Abstract][Full Text] [Related]
6. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
9. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
[TBL] [Abstract][Full Text] [Related]
10. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
12. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
[TBL] [Abstract][Full Text] [Related]
13. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
[TBL] [Abstract][Full Text] [Related]
14. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model.
Binka M; Janjua NZ; Grebely J; Estes C; Schanzer D; Kwon JA; Shoukry NH; Kwong JC; Razavi H; Feld JJ; Krajden M
JAMA Netw Open; 2020 May; 3(5):e204192. PubMed ID: 32374397
[TBL] [Abstract][Full Text] [Related]
16. Eliminating viral hepatitis C in Belgium: the micro-elimination approach.
Busschots D; Toghanian S; Bielen R; Salomonsson S; Koc ÖM; Hendrickx G; Jadoul M; Nevens F; Sokal E; Brixko C; Peerlinck K; Apers L; Robaeys G; Lazarus JV
BMC Infect Dis; 2020 Feb; 20(1):181. PubMed ID: 32106819
[TBL] [Abstract][Full Text] [Related]
17. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
18. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
19. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.
Lim AG; Qureshi H; Mahmood H; Hamid S; Davies CF; Trickey A; Glass N; Saeed Q; Fraser H; Walker JG; Mukandavire C; Hickman M; Martin NK; May MT; Averhoff F; Vickerman P
Int J Epidemiol; 2018 Apr; 47(2):550-560. PubMed ID: 29309592
[TBL] [Abstract][Full Text] [Related]
20. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
